Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trilipix CV Outcomes Study To Focus On Patients With High Triglycerides, Low HDL-Cholesterol

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA follows its advisory committee’s recommendation and requires a post-marketing study of Abbott’s fibrate to determine whether combination use with a statin provides a cardiovascular benefit over statin monotherapy in high-risk patients.

You may also be interested in...

ANCHOR Indication For Amarin’s Vascepa Will Face FDA Panel Scrutiny

Key question at the Oct. 16 advisory committee review could be whether FDA should wait for results from an ongoing cardiovascular outcomes trial before significantly broadening the prescription fish oil product’s approval to include adults with high triglycerides and mixed dyslipidemia.

Trilipix Advisory Committee Call For Outcomes Trial Could Be Damaged By Niaspan Failure

Abbott Laboratories is facing a difficult proposition with its cholesterol franchise. At the May 19 review of the ACCORD-Lipid data on use of Trilipix with a statin, FDA's Endocrinologic and Metabolic Drugs Advisory Committee called for outcomes trials to determine whether the combination has value in a particular subpopulation.

Could ACCORD Results Mean Another Trial For Trilipix?

Advisory committee says data inconclusive with subgroups and recommended another study to determine if there is increased risk in women and/or benefit for high TG, low HDL-C patients.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts